Replies to post #379118 on Innovation Pharmaceuticals Inc (IPIX)

[vip1999]

Top 10 biopharma M&As of 2021
https://www.nature.com/articles/d43747-021-00107-w
================
...
TABLE 1 | TOP TEN MERGERS AND ACQUISITIONS BY TOTAL DEAL VALUE IN 2021
Seller

Buyer

Date

Total deal value ($ million)

Upfront payment and cash equity ($ million)

Stage at deal announced

Assets involved

GW Pharmaceuticals

Jazz Pharmaceuticals

February 2021

$7,200

$7,200

Approved

Approved: Epidiolex.

Translate Bio

Sanofi

August 2021

$3,200

$3,200

Phase 2

Phase 2: MRT5005, an inhaled mRNA for CF; phase 1: MRT5500, an mRNA vaccine for COVID-19 already partnered with Sanofi.

Viela Bio

Horizon Therapeutics

February 2021

$3,050

$3,050

Approved

Approved: Uplizna, a B cell-depleting humanized mAb for rare neuromyelitis optica spectrum disorder; phase 2: VIB4920 and VIB7734; phase 1: VIB1116.

TeneoBio

Amgen

July 2021

$2,500

$900

Phase 1

Phase 1: TNB-585, a bispecific T cell engager for metastatic castrate-resistant prostate cancer.

Five Prime Therapeutics

Amgen

March 2021

$1,900

$1,900

Phase 3

Phase 3: bemarituzumab, an anti-FGFR2b antibody.

Pandion Therapeutics

Merck & Co.

February 2021

$1,850

$1,850

Phase 1

Phase 1: PT101; TALON technology.

Constellation Pharmaceuticals

MorphoSys

June 2021

$1,700

$1,700

Phase 3

Phase 3: pelabresib, a BET inhibitor for myelofibrosis; phase 2: CPI-0209, a second-generation EZH2 inhibitor for hematological and solid tumors.

Kymab Group

Sanofi

January 2021

$1,500

$1,100

Phase 2

Phase 2a: KY1005, a human mAb targeting immune system regulator OX40L for moderate to severe atopic dermatitis.

Protomer Technologies

Eli Lilly and Co.

July 2021

$1,000

$1,000

Platform

Peptide and protein engineering platform.

Arvelle Therapeutics

Gruppo Angelini

January 2021

$960

ND

Approved

Approved: Cenobamate.

CF, cystic fibrosis; mAb, monoclonal antibody; ND, not disclosed. Data provided by DealForma, August 2021. Financials in US$ millions based on disclosed figures.